GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Quest Laboratories Ltd (NSE:QUESTLAB) » Definitions » Debt-to-EBITDA

Quest Laboratories (NSE:QUESTLAB) Debt-to-EBITDA : 0.36 (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Quest Laboratories Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Quest Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹38.5 Mil. Quest Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹12.3 Mil. Quest Laboratories's annualized EBITDA for the quarter that ended in Mar. 2024 was ₹142.5 Mil. Quest Laboratories's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.36.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Quest Laboratories's Debt-to-EBITDA or its related term are showing as below:

NSE:QUESTLAB's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.68
* Ranked among companies with meaningful Debt-to-EBITDA only.

Quest Laboratories Debt-to-EBITDA Historical Data

The historical data trend for Quest Laboratories's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quest Laboratories Debt-to-EBITDA Chart

Quest Laboratories Annual Data
Trend Mar21 Mar22 Mar23 Mar24
Debt-to-EBITDA
2.07 0.48 0.51 0.32

Quest Laboratories Quarterly Data
Mar21 Mar22 Mar23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial N/A N/A N/A 0.42 0.36

Competitive Comparison of Quest Laboratories's Debt-to-EBITDA

For the Drug Manufacturers - General subindustry, Quest Laboratories's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quest Laboratories's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Quest Laboratories's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Quest Laboratories's Debt-to-EBITDA falls into.


;
;

Quest Laboratories Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Quest Laboratories's Debt-to-EBITDA for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(38.513 + 12.296) / 157.406
=0.32

Quest Laboratories's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(38.513 + 12.296) / 142.528
=0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Quest Laboratories  (NSE:QUESTLAB) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Quest Laboratories Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Quest Laboratories's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Quest Laboratories Business Description

Traded in Other Exchanges
N/A
Address
Plot No. 45, Sector III, Pithampur Industrial Area, District Dhar, Pithampur, MP, IND, 454775
Quest Laboratories Ltd is engaged in the business of manufacturing pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. It produces various products, comprising ethical drugs, generic drugs, and over-the-counter drugs, and is also available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids.

Quest Laboratories Headlines

No Headlines